e3 ligase ligand-linker conjugates

Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride, incorporating an E3 ligase ligand and a linker, can be used as an immunomodulator for the treatment of cancer.

MC-VC-PABC-amide-PEG1-CH2-CC-885 is an Antibody-Drug Conjugate (ADC) that employs a protein-degrading agent (protac molecular glue, etc.).

(S,R,S)-AHPC-C3-NH2 hydrochloride (VH032-C3-NH2 hydrochloride) is an E3 ligase ligand-linker coupler that can be used for the synthesis of PROTAC compounds.

CC-885-CH2-PEG1-NH-CH3 TFA is an innovative degrader designed for the synthesis of novel antibody-based degrader conjugated active molecules (AnDC) [1] [2].

Thalidomide 4'-ether-PEG2-azide is a modified form of the cereblon (CRBN) inhibitor Thalidomide, created through click chemistry. Featuring an azide group, this compound can participate in copper-catalyzed azide-alkyne cycloaddition reactions (CuAAc) with alkyne-containing molecules. It serves as a ligand for E3 ubiquitin ligase and as a linker conjugate (E3LigaseLigand-Linker Conjugates) for use in PROTACs.

Thalidomide-O-C3-azide is a chemically modified version of the cereblon (CRBN) inhibitor Thalidomide through click chemistry. It features an azido group, enabling copper-catalyzed azide-alkyne cycloaddition reactions (CuAAc) with alkyne-containing molecules. Thalidomide-O-C3-azide serves as a ligand for E3 ubiquitin ligase and a component in E3 Ligase Ligand-Linker Conjugates, facilitating the synthesis of PROTACs.

Thalidomide-O-C5-azide is a modified form of the cereblon (CRBN) inhibitor thalidomide, created through click chemistry. It contains an azide group, enabling it to undergo copper-catalyzed azide-alkyne cycloaddition reactions (CuAAC) with alkynyl-containing molecules. Thalidomide-O-C5-azide serves as a ligand and linker conjugate for E3 ubiquitin ligase, facilitating the synthesis of PROTACs.

(S,R,S)-AHPC-C5-NH2 (VH032-C5-NH2) dihydrochloride is a synthetic E3 ligase ligand-linker conjugate, incorporating a VH032-based VHL ligand and a linker. This compound is utilized in the synthesis of PROTAC degraders targeting ERRα.

(S,R,S)-AHPC-C7-aminedihydrochloride is the dihydrochloride salt form of (S,R,S)-AHPC-C7-amine. The compound (S,R,S)-AHPC-C7-amine is a synthetic E3 ligase ligand-linker (E3ligaseligand-linker conjugate) that includes a VHL ligand based on VH032 and one linker. It is utilized for synthesizing PROTAC degraders targeting ERRα.

Lenalidomide 4'-PEG1-amine dihydrochloride is a Lenalidomide-based Cereblon ligand designed for the recruitment of CRBN protein. It can be linked to a protein ligand via a linker to form a PROTAC.

Lenalidomide 4'-PEG2-amine dihydrochloride is a Cereblon ligand derived from Lenalidomide, designed to recruit CRBN proteins. This compound can be conjugated with a protein ligand through a linker to create a PROTAC.

Pomalidomide 4'-alkylC2-azide (compound 2a) is an E3 ligase ligand-linker conjugate that includes a cereblon (CRBN) ligand based on Pomalidomide and a linker. It is utilized in the synthesis of PROTACs.

Pomalidomide 4'-alkylC3-azide (compound 2b) is an E3 ligase ligand-linker conjugate that includes a cereblon (CRBN) ligand derived from Pomalidomide and a linker. It is utilized in the synthesis of PROTACs.

Pomalidomide-5-C8-NH2 hydrochloride, a Pomalidomide-based cereblon (CRBN) ligand, is instrumental in the recruitment of CRBN protein. This compound can be linked to the protein ligand via a linker to form PROTAC [1].

Pomalidomide 4'-alkylC6-azide, a Pomalidomide-based cereblon (CRBN) ligand, facilitates the recruitment of CRBN protein. It is designed to attach to a protein through a linker, enabling the formation of PROTAC [1].

Lenalidomide 4'-PEG2-azide, a Lenalidomide-derived Cereblon ligand, facilitates the recruitment of CRBN protein. This compound can be tethered via a linker to a protein ligand, enabling the formation of PROTAC [1].

Lenalidomide 4'-alkyl-C5-azide, a functionalized cerebellar ligand designed for PROTAC development, comprises an E3 ligand and an alkyl LC5 ligand featuring terminal azides for coupling with a target protein ligand [1].

(S,R,S)-AHPC-C2-PEG3-BCN (Compound 16b) serves as a VHL ligand and is applicable in the synthesis of PROTACs [1].'

Thalidomide-NH-C4-NH-Boc is a synthesized conjugate used in PROTAC technology, combining a Thalidomide-based cereblon ligand with a linker.

Thalidomide-O-C6-NH2 hydrochloride (4-((6-aminohexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride) is a synthesized E3 ligase ligand-linker conjugate.

Thalidomide-O-amido-C3-NH2 TFA (Cereblon Ligand-Linker Conjugates 16 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating a Thalidomide-based cereblon ligand and a linker used in PROTAC technology.

Thalidomide-NH-C2-PEG3-OH (H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-4-[[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]amino]-) is an E3 ligase ligand-linker conjugate.

Thalidomide-PEG4-Propargyl (Thalidomide-O-PEG4-Propargyl) is a synthetic E3 ligase ligand-linker conjugate containing a Thalidomide-based cereblon ligand and a linker which can be used in PROTAC technology[1].

Pomalidomide-PEG4-C-COOH (E3 Ligase Ligand-Linker Conjugates 1) is a synthesized E3 ligase ligand-linker conjugate that combines the Pomalidomide-based cereblon ligand and 4-unit PEG linker used in PROTAC technology.